Enzymotec Launches Cognitive Innovation
The new launch of GPC is a part of Enzymotec's overall strategy to offer a full line of cognitive solutions aimed to different age groups, mental capacity and price.
12/06/06 Enzymotec has announced the launch of a new cognitive ingredient – alphaGPC.
L-α-glycerophosphrylcholine (also known as alpha-GPC or choline alphoscerate), has been used for some time as a dietary supplement aiming to improve mental performance. It serves as a precursor for reconstituting nerve cell membrane component. Clinical trials over the past two decades have demonstrated that providing choline as GPC to patients with adult-onset dementia disorders favour memory and attention. The clinical efficacy of GPC (1,000-1,200 mg/d) has been associated in these studies with protection against cognitive impairment characteristics of dementia disorders.
The new launch of GPC is a part of Enzymotec's overall strategy to offer a full line of cognitive solutions aimed to different age groups, mental capacity and price. The company recently launched the SharpPS gold grade, which provides a PS-DHA conjugate, capable of enhancing PS's cognitive effect, through its unique combination with DHA.
Enzymotec is an Israeli biotech company, which develops and manufactures bio-functional ingredients for the dietary supplements, functional foods and infant formula markets. Its key product categories are: SharpPS - phosphatidylserine for brain improvement, InFat - structured fat for infant formulas, which mimics mother's milk capacity to increase Calcium and energy intake and CardiaBeat - for reducing several CVD-risk factors simultaneously.
